The Legal Cannabis Market Maintains Growth

Friday, March 24, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, March 24, 2017 /PRNewswire/ -- News Commentary 

According to new data

published Arcview Market Research, a leading publisher of cannabis market research, the legal cannabis market is projected to continue to grow at a 27 percent CAGR through 2021, despite conflicting signals from the current presidential administration.
The report created by Arcview's data partner, BDS Analytics, points out that the two biggest drivers of growth in this industry are the passage and subsequent implementation of new adult-use laws and branded product subcategories. Examples of these subcategories would be vape cartridges, edibles, and other alternative consumption methods. Invictus MD Strategies Corporation (OTC: IVITF) (CSE: IMH.CN), Cannabis Science Inc. (OTC: CBIS), Medical Marijuana Inc. (OTC: MJNA), Easton Pharmaceuticals Inc. (OTC: EAPH), CV Sciences Inc. (OTC: CVSI).  

Troy Dayton, CEO of Arcview Market Research, said in a statement, "While the uncertainty created by the mixed signals coming out of the administration may cause a temporary dip in some valuations of cannabis companies and some more risk-averse institutional investors and multinational companies may continue to stay on the sidelines, it won't impact the growth of the market much at all. No matter what the administration does, states will continue to issue cannabis licenses to a long line of applicants and licensed cannabis outlets will continue to have long lines of consumers ready to purchase this product from regulated establishments."

Invictus MD Strategies Corporation (OTC: IVITF) (CSE: IMH.CN) is focused on three main verticals within the burgeoning Canadian cannabis sector: Licensed Producers under the Access to Cannabis for Medical Purposes Regulations ("ACMPR"); Fertilizer and Nutrients through Future Harvest Development Ltd.; and Cannabis Data and Delivery, with its wholly owned subsidiary Poda Technologies Ltd.

Invictus MD Strategies Corp. this week announced, "that AB Laboratories Inc. (AB Labs) has successfully completed several test crops in its licensed production facility under the Access to ACMPR located in Hamilton, Ontario. The facility, which was licensed for cultivation under the ACMPR in October 2016, is currently operating at half capacity, with full production capacity scheduled by the end of May 2017. AB Labs has already received several direct inquiries from patients, which underscores the continuously growing demand."

Dan Kriznic, Chairman and CEO of Invictus MD, stated, "We are very pleased to see the speed at which AB Labs has been able to secure starter material, strains and potential offtake partners for production. In addition, considering the magnitude of AB Ventures' land acquisition and future facility, and assuming AB Ventures obtains a license to produce the quantity forecasted for the proposed facility, the combined production capacity of both AB Labs and AB Ventures is expected to exceed 20,000 kilograms in 2019. Invictus MD currently has approximately $15.5 million in cash and is fully funded for the initial expansion plans with AB Ventures. Construction plans are already underway and expect to be submitted to Health Canada by May 1, 2017." 

Cannabis Science Inc. (OTC: CBIS) uses an inquiring approach to discover and develop novel cannabinoid-based therapies to improve patients' lives. The company announced the anticipated delivery of its very first pre-designed greenhouses with full tracking and reporting protocols to its California and Nevada operations. "Having control over our own supply chain will greatly increase our efficiencies, including the time and cost required to have processed products readily available for development into all our formulations. We will soon launch our observational studies for specific cannabinoid combinations targeting critical ailments. We will be growing a variety of cannabinoid combinations for our formulations and testing. Each formulation is designed to target a specific critical ailment; to work using a particular delivery mode; and to have the potency to drive maximum positive results in patient usage," stated CMO, Dr. Allen Herman.

Medical Marijuana Inc. (OTC: MJNA) announced that its major investment company, that is a leader in cannabinoid research and development, AXIM® Biotechnologies Inc., has retained the services of Ora®, Inc., a global Contract Research Organization (CRO), to perform the company's upcoming product development and clinical trials for treating glaucoma and dry eye utilizing cannabinoid-based therapeutics. Ora is the world's leading ophthalmology CRO for advancing products from pre-clinical through approval and post-market phases. "It is exciting to see AXIM start on pre-clinical efforts alongside esteemed ophthalmology professionals to develop a cannabinoid-based eye drop medication that may assist glaucoma sufferers," said Dr. Stuart Titus, CEO of Medical Marijuana, Inc. "This partnership between AXIM and Ora is another new exciting milestone for AXIM's clinical development program, as it continues to move forward finding cannabinoid-based solutions for conditions for which there is no effective treatment."

Easton Pharmaceuticals Inc. (OTC: EAPH) is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other growing industries. The company has re-initiated discussions with Medicated Markets International LLC towards assets and relationships it has developed in California's Medical Marijuana industry and other jurisdictions throughout the world. With California and other States recent legalization of Medical Marijuana has opened up new opportunities for Easton Pharmaceuticals and its partners. Easton will continue to make the burgeoning medical marijuana, Vaporizer and e-liquids industry a priority and will continue to strive to be a big part of this sector moving forward.

CV Sciences Inc. (OTCQB: CVSI) is a life science company. The company operates in two segments: specialty pharmaceuticals and consumer products. CV Sciences' Pharmaceutical Division is developing synthetically-formulated cannabidiol-based medicine, pursuing the approval of the U.S. Food and Drug Administration for drugs with specific indications utilizing cannabidiol as the active pharmaceutical ingredient. CV Sciences has achieved promising preclinical results in the development of cannabinoid medicines for treatment of a range of medical conditions. CV Sciences' Consumer Products Division delivers botanical-based cannabidiol products that enhance quality of life. Currently distributed nationally in health food stores, health care provider's offices and online, each consumer products brand is backed by a formal safety review, growing body of case reports, and physician's recommendations.

Please SIGN UP NOW at To Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"

Subscribe Now! Watch us report from NYSE

Follow us on Twitter for real-time Financial News Updates:

Follow and talk to us on Instagram:

Facebook Like Us to receive live feeds:

About, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. has not been compensated directly by any of the companies mentioned here in this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions as we purely incorporate public market research along with financial and corporate news. only regurgitates financial or corporate news through our unique financial newswire and media platform. For this release, has been compensated a total of seven thousand dollars for financial news dissemination and pr services by a third party non affiliate for invictus md strategies corporation. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit:

For further information: +1-877-601-1879 Url:



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store